MedAssets Shares Jumped: What You Need to Know

Before you go, we thought you'd like these...
Before you go close icon

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of medical product maker MedAssets (NAS: MDAS) was miraculously cured today, sending the stock 19% higher.

So what: Revenue grew 50% to $143.7 million and adjusted earnings per share increased a penny to $0.26 per share. Analysts were only expecting revenue of $137.6 million and earnings per share of $0.17, so the results crushed what the "experts" thought.

Now what: When you take out the acquisition of Broadlane, the results aren't quite as eye-popping with adjusted revenue increasing only 2.5%. Nevertheless, beating expectations is always a welcome sight, and with shares trading at just 11 times forward earnings estimates, it looks like there's plenty of upside. MedAssets has now beaten estimates the last three quarters, and I think shares have more room to run.

Interested in more info on MedAssets? Add it to your watchlist byclicking here.

At the time this article was published Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners